Analysts Conflicted on These Healthcare Names: MoonLake Immunotherapeutics (MLTX), Sarepta Therapeutics (SRPT) and vTv Therapeutics (VTVT)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on MoonLake Immunotherapeutics (MLTX – Research Report), Sarepta Therapeutics (SRPT – Research Report) and vTv Therapeutics (VTVT – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
MoonLake Immunotherapeutics (MLTX)
In a report released today, Yun Zhong from Wedbush maintained a Buy rating on MoonLake Immunotherapeutics, with a price target of $34.00. The company’s shares closed last Tuesday at $18.34.
According to TipRanks.com, Zhong has 0 stars on 0-5 stars ranking scale with an average return of
Currently, the analyst consensus on MoonLake Immunotherapeutics is a Moderate Buy with an average price target of $28.00, a 53.7% upside from current levels. In a report issued on February 25, TipRanks – Google also upgraded the stock to Buy with a $20.00 price target.
See the top stocks recommended by analysts >>
Sarepta Therapeutics (SRPT)
Piper Sandler analyst Biren Amin maintained a Hold rating on Sarepta Therapeutics today and set a price target of $16.00. The company’s shares closed last Tuesday at $17.66.
According to TipRanks.com, Amin is a 4-star analyst with an average return of
Sarepta Therapeutics has an analyst consensus of Hold, with a price target consensus of $21.00, which is a 19.1% upside from current levels. In a report issued on February 25, Goldman Sachs also maintained a Hold rating on the stock with a $17.00 price target.
vTv Therapeutics (VTVT)
Roth MKM analyst Adam Walsh reiterated a Buy rating on vTv Therapeutics today and set a price target of $58.00. The company’s shares closed last Tuesday at $35.02.
Walsh has an average return of
According to TipRanks.com, Walsh is ranked #3512 out of 12124 analysts.
vTv Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $55.25, implying a 50.7% upside from current levels. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $47.00 price target.
